Selectivity and Maximum Response of Vibegron and Mirabegron for β3-Adrenergic Receptors
Authors:
Open Access
- 14 May 2022
- journal article
- research article
- Published by Elsevier in Current Therapeutic Research
- Vol. 96, 100674
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adultsCochrane Database of Systematic Reviews, 2012
- Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU GuidelineJournal of Urology, 2012
- Beta-Adrenergic Receptors, from Their Discovery and Characterization through Their Manipulation to Beneficial Clinical ApplicationCardiology, 2012
- The prevalence of chronic constipation and faecal incontinence among men and women with symptoms of overactive bladderBJU International, 2011
- An international urogynecological association (IUGA)/international continence society (ICS) joint report on the terminology for female pelvic floor dysfunctionNeurourology and Urodynamics, 2009
- Effect of (R)-2-(2-Aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} Acetanilide (YM178), a Novel Selective β3-Adrenoceptor Agonist, on Bladder FunctionThe Journal of Pharmacology and Experimental Therapeutics, 2007
- A Quantitative Analysis of mRNA Expression of α1 and β-adrenoceptor Subtypes and Their Functional Roles in Human Normal and Obstructed BladdersJournal of Urology, 2003
- β3-adrenoceptors in human detrusor muscleUrology, 2002
- Functional and molecular biological evidence for a possible β3‐adrenoceptor in the human detrusor muscleBritish Journal of Pharmacology, 1999
- Molecular Characterization of the Human β 3 -Adrenergic ReceptorScience, 1989